Ondine Biomedical Inc. (AIM: OBI), the Canadian life sciences company specialising in light-activated antimicrobial therapies, has announced that Dartford and Gravesham NHS Trust (DGT) is adopting its Steriwave® nasal photodisinfection technology for elective orthopaedic surgery. The deployment, made possible through Ondine's UK distribution partner Mölnlycke Health Care, marks further commercial momentum for the company within NHS surgical pathways. DGT serves a population of over 500,000 residents across North Kent and operates its main acute services from Darent Valley Hospital, making it a significant addition to Ondine's growing NHS customer base.

Key Points

  • Ondine Biomedical Inc. (AIM: OBI) is a Canadian life sciences company focused on photodisinfection therapies
  • Dartford and Gravesham NHS Trust has adopted Steriwave® nasal photodisinfection for its elective orthopaedic surgery pathway
  • Steriwave holds NHS Supply Chain Innovation Product classification; real-world data from other trusts report SSI reductions of 71% and 78% respectively
  • Investors may watch for further NHS Trust adoptions and progress in the ongoing US Phase 3 clinical trial

Dartford and Gravesham NHS Trust Integrates Steriwave into North Kent Orthopaedic Pathway

DGT is described in the announcement as one of the largest healthcare providers in North Kent, covering Dartford, Gravesham, Swanley, and the London Borough of Bexley. According to the disclosure, the trust has integrated Steriwave into its elective orthopaedic surgical pathway, with the five-minute, clinician-administered treatment deployed to reduce nasal microbial burden immediately before surgery. The announcement notes that treatment has so far been organised in under 24 hours within patient cohorts at DGT's QMH site, helping the trust make better use of available theatre time that might otherwise have gone unused.

Steriwave's Non-Antibiotic Mechanism Addresses NHS Antimicrobial Stewardship Priorities

Steriwave uses a light-activated antimicrobial agent combined with red light to target pathogens in the nose, a recognised reservoir for bacteria associated with surgical site infections. As a non-antibiotic, point-of-care intervention, it reduces reliance on multi-day home-based decolonisation regimens, which the announcement suggests supports NHS antimicrobial stewardship goals. GIRFT data cited in the announcement indicate that patients who develop SSIs following elective hip and knee surgery require an additional two to four weeks of inpatient care, underscoring the clinical and operational burden that infection-prevention technology such as Steriwave aims to address.

Real-World NHS Data and Supply Chain Status Underpin Commercial Case for OBI

The announcement references real-world outcomes data from two NHS trusts. Leeds Teaching Hospitals NHS Trust reported a 78% reduction in SSIs in high-risk endoscopic anterior skull-base surgeries, whilst Mid Yorkshire Teaching NHS Trust recorded a 71% reduction in SSIs across elective hip and knee replacements. Health economic analysis by the York Health Economics Consortium found Steriwave to be a cost-saving intervention, the announcement states. Steriwave's classification as an NHS Supply Chain Innovation Product means it is readily accessible to NHS providers nationally, which the disclosure suggests could support broader adoption across surgical specialties.

US Phase 3 Trial Enrolment Complete as Ondine Builds International Pipeline

Beyond the UK, Ondine Biomedical's announcement notes that Steriwave has recently completed enrolment in its Phase 3 clinical trial in the United States, where the technology holds both Qualified Infectious Disease Product designation and Fast Track status from the US Food and Drug Administration. The product is not currently approved for commercial use in the US and remains limited to investigational use under US law. Ondine also maintains a broader pipeline of photodisinfection applications targeting chronic sinusitis, ventilator-associated pneumonia, and burns, indicating potential longer-term revenue diversification beyond nasal decolonisation.